Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. - Wikidata - awgldk - TriplyDB

Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.

Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.

http://www.wikidata.org/entity/Q34819581

about

Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond Cardiac energy metabolic alterations in pressure overload-induced left and right heart failure (2013 Grover Conference Series)Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension p53 and TIGAR regulate cardiac myocyte energy homeostasis under hypoxic stress.The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.Is treatment with trimetazidine beneficial in patients with chronic heart failure?Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.Imaging and modeling of myocardial metabolism Translation of myocardial metabolic imaging concepts into the clinics.Glucose metabolism and cardiac hypertrophy Persistent overexpression of phosphoglycerate mutase, a glycolytic enzyme, modifies energy metabolism and reduces stress resistance of heart in mice Hyperpolarized magnetic resonance: a novel technique for the in vivo assessment of cardiovascular disease.Fatty heart, cardiac damage, and inflammation.Assessment of myocardial metabolic flexibility and work efficiency in human type 2 diabetes using 16-[18F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer.Trimetazidine does not alter metabolic substrate oxidation in cardiac mitochondria of target patient population.Accelerated (99m)Tc-sestamibi clearance associated with mitochondrial dysfunction and regional left ventricular dysfunction in reperfused myocardium in patients with acute coronary syndrome.Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure.A "PET" area of interest: myocardial metabolism in human systolic heart failure.The effects of trimetazidine on lipopolysaccharide-induced oxidative stress in mice.Sarcolemmal fatty acid uptake vs. mitochondrial beta-oxidation as target to regress cardiac insulin resistance.Lipid Use and Misuse by the Heart.Recovery of Serum Cholesterol Predicts Survival After Left Ventricular Assist Device Implantation Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure.Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure.Metabolic remodelling in human heart failure.Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents.Lipid metabolism and toxicity in the heart.Cardiac metabolism in hypertrophy and heart failure: implications for therapy.Myocardial energetics in heart failure.Recent advances in metabolic imaging.Trimetazidine and cardioprotection: facts and perspectives.Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.Trimetazidine in Practice: Review of the Clinical and Experimental Evidence.Novel investigational therapies for treating pulmonary arterial hypertension.Imaging of myocardial fatty acid oxidation.Emerging drugs for the treatment of angina pectoris.The Modulating Effects of Cardiac Resynchronization Therapy on Myocardial Metabolism in Heart Failure.Metabolic support for the heart: complementary therapy for heart failure?Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle.

P2860

Q24605881-62B3B883-D442-4391-BF19-6C20FE71522A Q24645066-F50039E3-53CB-42B3-B989-5B5E90FF770B Q26825047-41F09274-2AF4-460F-9D99-E27869E66E02 Q28083183-5CB772F9-611F-45B3-963C-37CB6CD8FBC2 Q29347283-27984AA5-ADC5-477B-8D2E-BB9C2D7994C0 Q30585014-71C3C4DF-E081-4A8F-ACA3-1CFFB370AB26 Q33567682-CF38F655-2AF4-4041-9297-1BC32971188A Q33603593-127BF35C-0541-4D4A-8AEC-50A7A3ED9CA4 Q33970067-80E9BA60-1FD2-472D-9AC6-1D96603AC1CB Q34089975-7F1C35BA-319B-4E0A-BF15-25C58B13201C Q34808553-1A39D239-CEE2-4F82-9881-738CF0FE53C5 Q34951279-57E3C7E2-267E-4B39-AF85-08BEFB4BA7FD Q35298233-F2C8DF81-F723-468A-83C8-553222E76B1E Q35760308-7B2BF1BC-4993-4F99-A1B0-3A7EEF5F37FD Q36698721-5E2B5AEE-6C2F-4A91-A839-FD6DAC3FF2BF Q36797382-258E13FA-B6C1-4ED6-B0C5-3FB97008F5DD Q36894995-ABB5C936-7867-4BA9-9D3C-31C3ED60A506 Q36896507-96547D8D-5676-4B9E-868D-DB966EC604AA Q37086847-95B074A8-3CD9-412D-B118-8CFBA43E48D0 Q37413807-FB6501F0-62E8-45EC-9556-7ED87540FB35 Q37486065-632CF532-4BA0-4E3E-9491-E1560290BF85 Q37684850-E9D6C48F-3768-486D-B3E1-301142248BFA Q37733657-9DB4AE39-23D5-4D65-A4D1-BB392C3BF350 Q37785792-3FC42330-EB5C-411C-87AE-6D12C9E8AEBD Q37812007-35A802DB-5091-4D4C-9C37-CC24CBB83E4C Q37849446-93570343-B6EB-4516-94E8-B2EDCA16E976 Q37858515-F7E58AA6-3D00-480C-8DEF-2B388EC53FF1 Q38017379-DE6C2FC0-A16E-400D-81E4-C9BD579C1AD7 Q38057699-50DBEAB7-7148-4B06-AEB4-C9B26D0F83E9 Q38112349-1519FB55-A867-4141-B97A-9AD93A4B1C00 Q38156683-6EEE0942-7354-42CF-B07D-C46C1E20FEC3 Q38203492-EE106DDE-CA90-4DB3-9F31-3E12F518F69A Q38217985-D4E3BA7B-8CCD-4661-8A51-43E808596D8A Q38371888-87ACEA3D-0FED-4F58-B390-0306CF30AABE Q38612061-4401751F-9190-480F-B33B-C4FD08158719 Q38753602-3F3EED5F-4868-4554-89CF-055080EFE502 Q38967994-70FA8185-746A-453C-A53C-2144D8FE507A Q38997240-164B2F15-2058-486C-8418-BF833186A88D Q38998576-EA07C66F-04C4-4382-A350-5DA6CC376D81 Q40096264-F87F6E8B-AB09-4013-B523-39C77009DC46

P2860

Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.

http://www.wikidata.org/entity/Q34819581

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Trimetazidine, a metabolic mod ...... pathic dilated cardiomyopathy.

@ast

Trimetazidine, a metabolic mod ...... pathic dilated cardiomyopathy.

@en

Trimetazidine, a metabolic mod ...... pathic dilated cardiomyopathy.

@nl

type

label

Trimetazidine, a metabolic mod ...... pathic dilated cardiomyopathy.

@ast

Trimetazidine, a metabolic mod ...... pathic dilated cardiomyopathy.

@en

Trimetazidine, a metabolic mod ...... pathic dilated cardiomyopathy.

@nl

prefLabel

Trimetazidine, a metabolic mod ...... pathic dilated cardiomyopathy.

@ast

Trimetazidine, a metabolic mod ...... pathic dilated cardiomyopathy.

@en

Trimetazidine, a metabolic mod ...... pathic dilated cardiomyopathy.

@nl

P1433

Q34819581-9ADDA17D-5B3B-42CA-A212-F549BD55EC74

P1476

Q34819581-3D4CA753-870B-4AA6-9B57-3387F82DFE3A

P2093

Q34819581-08D51FE7-8BA3-4790-9DE4-F428A044DD16

Q34819581-2A8DF391-DDDC-4D1D-9E35-47B9536F79EA

Q34819581-411A05AC-EC86-4AFB-A43C-78BF2ECB05EA

Q34819581-48BDC325-4FA4-487B-8FBE-CC850EACB687

Q34819581-58A666B0-E145-494B-8195-404FA6A76681

Q34819581-B5851E59-75F9-454B-9C87-1B71D0978A8B

Q34819581-D23072AE-3509-45A9-8FBA-EA7BA93DECB0

Q34819581-E34C814B-E56F-45AB-8F69-0D509748B978

Q34819581-FA32738C-E799-41B3-B4F7-B4B06622AC93

P304

Q34819581-26598B5E-4700-45EE-BD9C-567A7957AA14

P31

Q34819581-1B9DB5A1-868D-4B1F-A7F7-444380E174C1

P356

Q34819581-A037DC2A-836C-4398-8CBC-F546C56829A2

P407

Q34819581-E0D51325-37DD-4BE3-8EB0-7D1A888397F2

P433

Q34819581-FBB6FAA7-9BBA-4B98-83A8-E21ECE6C3B3B

P478

Q34819581-B3508334-4158-47EC-BBDC-331C895E393E

P50

Q34819581-11F1B64B-24F5-43D5-BDBA-5487AC571B2B

Q34819581-1EDC44E6-40A4-4FC8-837C-475976A312DC

Q34819581-454E0647-38D6-4C96-B035-E85FC262025D

P577

Q34819581-1CEFBD5E-B581-4DAF-9CF1-B1A8E04B48F8

P698

Q34819581-50490481-481A-4631-8CD9-06AFCC8E18C0

P356

CIRCULATIONAHA.108.778019

P1433

P1476

Trimetazidine, a metabolic mod ...... pathic dilated cardiomyopathy.

@en

P2093

Alexandru Naum

http://www.w3.org/2001/XMLSchema#string

Birger Hesse

http://www.w3.org/2001/XMLSchema#string

Erik Engblom

http://www.w3.org/2001/XMLSchema#string

Heikki Ukkonen

http://www.w3.org/2001/XMLSchema#string

Helena Tuunanen

http://www.w3.org/2001/XMLSchema#string

K E Juhani Airaksinen

http://www.w3.org/2001/XMLSchema#string

Kjell Någren

http://www.w3.org/2001/XMLSchema#string

Mika Scheinin

http://www.w3.org/2001/XMLSchema#string

Pirjo Nuutila

http://www.w3.org/2001/XMLSchema#string

P304

1250-1258

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.108.778019

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18765391

http://www.w3.org/2001/XMLSchema#string